ISBT 001
ABO
A, B, AB, and O patterns depend on A/B transferase activity layered on H substance.
Genes: ABO
Antigens: A, B, A1
Education First
Site section 6 of 12A professional transfusion-literacy course on ABO/RhD, ISBT systems, antigens, antibodies, testing workflows, component rules, rare blood, pregnancy and neonatal context, chronic transfusion, transplant, and emergency-boundary logic.
Learning progress
Progress is private to this browser.
Core instrument
The first live interaction makes the shortcut visible: a label is produced from surface antigens, but the real workflow also needs method, component, history, and scenario context.
Antigen antibody builder
Toggle the surface antigens and read the summary label and the antibodies the plasma is expected to hold.
Summary label
A, RhD-positive label
Expected antibody pattern
expected anti-B
Group A: the plasma holds what the cells lack.
expected anti-B. A and B antibodies arise without exposure, against the ABO antigens the cells do not carry. RhD is present, so anti-D does not arise. The label summarizes the surface; component, history, antibody screen and crossmatch decide the laboratory workflow.
Summary label A, RhD-positive label. Expected antibody pattern: expected anti-B.
A, B built on H; plasma anti-A, anti-B against the ABO antigens absent; no H: anti-A, anti-B, anti-H
What it shows: A schematic red-cell surface with the H, A, B and RhD antigens, and the ABO/H antibodies the plasma is expected to hold for that surface.
How to read it: Each toggle adds or removes one antigen. A and B are sugars added to the H antigen, so with H absent they draw as empty outlines and the label reads the Oh (Bombay) pattern.
Assumptions: Expected antibodies follow Landsteiner’s rule for ABO; anti-D is immune and appears only after exposure. Subgroups, secretor status and unexpected antibodies are outside the model.
Check yourself
A learner sees an ABO/Rh label and wants to treat it as a complete compatibility answer. The course has to force the missing evidence back into view.
Choose the next move
Pick an answer to see why.
Professional course contract
Every idea here is an antigen, an antibody, an allele or phenotype, a method, a component, a scenario, or a limitation. The course builds from ABO/RhD into non-ABO systems, crossmatch logic, discrepancy handling, and high-stakes boundaries.
Testing
The course teaches where observations come from, why discrepancies happen, and when a case leaves the beginner chart.
Agglutination simulator
Set the synthetic cells and plasma, and read the forward and reverse wells, each graded 0 to 4+, and whether the two typings agree.
Forward type
A
RhD positive
Reverse type
A
Concordance
concordant
Forward and reverse agree: A.
The cells carry the antigens of group A and the plasma holds the antibodies that group is expected to carry, all at full strength. Agreement is the precondition for recording a type, not a compatibility decision.
Forward A, RhD positive; reverse A; concordant. Wells: anti-A 4+, anti-B 0, anti-D 3+, control 0, A1 cells 0, B cells 3+.
forward: anti-A, anti-B on the cells; reverse: A1, B cells in the plasma; concordant when both give one group at full strength
What it shows: A synthetic tube typing. Antisera find the antigens on the cells (forward); reagent A1 and B cells find the antibodies in the plasma (reverse). Each well is graded on the 0 to 4+ scale.
How to read it: A present antigen reacts 4+ (1+ for a weak subgroup); anti-D reacts 3+ (1+ for weak D). Expected plasma antibodies react 3+ (1+ when weak). A second population of group O RhD negative cells reacts with nothing, so a forward well reacts in only part of the cells: a mixed field.
Acceptance and scale: Discrepant when the forward and reverse groups differ; resolve first when they agree but a reaction is weak, a mixed field shows, or anti-D is weak; concordant only otherwise.
Assumptions: Forward ABO below 3+ and reverse below 2+ count as weaker than expected. Cold autoantibodies, rouleaux and unexpected antibodies are outside the model, and the control well stays clean.
The course teaches how observations are produced before it teaches what they can organize. Each method has a specimen, reagent context, output, limitation, and escalation path.
Components
Red cells, plasma, platelets, cryoprecipitate, whole blood, transplant, and emergency release all carry different questions.
Select the component first. The course refuses to reuse one chart for red cells, plasma, platelets, cryoprecipitate, whole blood, transplant, and emergency contexts.
Red-cell ABO compatibility is antigen-on-donor-cell versus antibody-in-recipient-plasma logic.
System atlas
The atlas exposes ISBT system scale and shows why Kell, Duffy, Kidd, MNS, Diego, Lewis, P1PK, GLOB, Lutheran, Dombrock, Colton, Yt, Xg, Scianna, Cromer, Knops, Vel, Lan, CD36, MAL, and PIGZ exist in the course contract.
ISBT 001
A, B, AB, and O patterns depend on A/B transferase activity layered on H substance.
Genes: ABO
Antigens: A, B, A1
ISBT 018
H antigen is the substrate for A and B antigen expression on red cells.
Genes: FUT1
Antigens: H
ISBT 004
D, C, c, E, and e are inherited through RHD/RHCE variation and can include weak or partial expression.
Genes: RHD, RHCE
Antigens: D, C, c, E, e
ISBT 006
K and k are core teaching antigens; K is important in transfusion and pregnancy literacy.
Genes: KEL
Antigens: K, k, Kpa, Kpb, Jsa, Jsb
ISBT 008
Fya and Fyb expression varies by allele and promoter context.
Genes: ACKR1
Antigens: Fya, Fyb
ISBT 009
Jka and Jkb are core antigens; Kidd antibodies can become hard to detect over time.
Genes: SLC14A1
Antigens: Jka, Jkb
ISBT 002
M, N, S, s, and U are the central teaching antigens.
Genes: GYPA, GYPB
Antigens: M, N, S, s, U
ISBT 010
Dia and Dib are central Diego teaching antigens.
Genes: SLC4A1
Antigens: Dia, Dib
ISBT 007
Lea and Leb expression depends on Lewis and secretor biology.
Genes: FUT3
Antigens: Lea, Leb
ISBT 003
P1 and related antigens connect to P-system literacy.
Genes: A4GALT
Antigens: P1
ISBT 028
P antigen context is distinguished from P1PK in the atlas.
Genes: B3GALNT1
Antigens: P
ISBT 005
Lua and Lub are core Lutheran teaching antigens.
Genes: BCAM
Antigens: Lua, Lub
High-stakes contexts
These modules explain what changes the laboratory question while refusing to provide personal or emergency instructions.
Capstone
The workbench trains learners to separate known facts from missing context, then hand the real decision back to qualified teams.
Each capstone case ends with known facts, missing information, the highest-risk misunderstanding, and what this course cannot decide.
ABO discrepancy
Highest-risk failure: Treating a discrepancy as a normal ABO group before resolution.
Source record
Each medical, laboratory, and regulatory statement in this course traces to one of these authorities, with the date it was read.
ISBT Red Cell Immunogenetics and Blood Group Terminology
2026-07-02International Society of Blood Transfusion / Official registry
Official blood group system and terminology governance.
ISBT Blood Group Database
2026-07-02International Society of Blood Transfusion / Official registry
Blood group systems, antigens, genes, and allele records.
ISBT table of blood group systems
2026-07-02International Society of Blood Transfusion / Official registry
Current source check for system scale and nomenclature.
Standards for Blood Banks and Transfusion Services, 35th edition
2026-07-02AABB / Standard
Current transfusion-service standards context.
Circular of Information for the Use of Human Blood and Blood Components
2026-07-02AABB, America’s Blood Centers, American Red Cross, and Armed Services Blood Program / Standard
Component, compatibility, and transfusion information boundary.
FDA guidance recognizing the June 2024 Circular of Information
2026-07-02FDA / Regulation
Regulatory anchor for the recognized Circular of Information.
Blood Groups and Red Cell Antigens
2026-07-02NCBI Bookshelf / Textbook
Background on red cell antigens, ABO, Rh, and non-ABO systems.
Pre-transfusion testing
2026-07-02Canadian Blood Services Professional Education / Professional education
Testing sequence, type and screen, antibody screen, and crossmatch concepts.
Guidelines for pre-transfusion compatibility procedures
2026-07-02British Society for Haematology / Guideline
Compatibility testing and discrepancy-resolution context.
Sickle Cell Disease Guidelines: Transfusion Support
2026-07-02American Society of Hematology / Guideline
Chronic transfusion, extended antigen support, and SCD-specific context.
Prevention of Rh D Alloimmunization
2026-07-02American College of Obstetricians and Gynecologists / Guideline
RhD alloimmunization and pregnancy education boundary.
Component compatibility
2026-07-02Australian Red Cross Lifeblood / Professional education
Component-specific compatibility teaching anchor.
Blood types
2026-07-02American Red Cross / Plain-language education
Plain-language ABO/RhD and rare blood framing.
OPTN policies
2026-07-02Health Resources and Services Administration / Regulation
Transplant policy context for ABO-related concepts.
21 CFR 606 current good manufacturing practice for blood and blood components
2026-07-02Electronic Code of Federal Regulations / Regulation
Blood and blood-component regulatory background.
42 CFR 493 laboratory requirements
2026-07-02Electronic Code of Federal Regulations / Regulation
Clinical laboratory regulatory background.
Course boundary
This course teaches language, systems, and laboratory workflow. It does not provide personal transfusion, pregnancy, donation, transplant, or emergency decisions.
Educational transfusion-literacy context only; not medical advice, transfusion instruction, emergency guidance, pregnancy management, donor eligibility advice, diagnosis, treatment guidance, dosing guidance, administration guidance, or evidence that any catalog item changes a biological outcome. The course uses synthetic educational cases only. Real transfusion, pregnancy, donation, transplant, and emergency decisions belong to qualified clinical and laboratory teams.
Editorial scope: chemical identity, experimental context, analytical methods, source quality and regulatory boundaries. Source references and stated limitations form part of the material; they should remain attached to quotations or summaries.
Lab and biomarker literacy path
Why it matters
Greater transparency today drives better research tomorrow. We provide the materials and the data so the next breakthrough is one step closer.
Our mission